Q-omics provides the consensus-scored ZNF132 profile across patient tissues and cancer cell-line models. ZNF132 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF132 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ZNF132 RNA expression shows 20,120 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where ZNF132 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF132 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF132 survival associations across molecular data types. ZNF132 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF132 RNA expression–survival associations across cancer types. High ZNF132 expression shows unfavorable associations in LGG, but favorable associations in KIRC, SCLC, HNSC, PAAD and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF132 RNA expression.
This table summarizes ZNF132 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF132. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF132 shows lower tumor expression in COAD, THCA, KIRC, KICH, HNSC and UCEC. The COAD box plot shows higher ZNF132 RNA expression in normal versus tumor tissue (log2 FC = −0.699, t-test p < 0.001).
This table shows molecular features associated with ZNF132 in patient tissues and cancer cell lines. In patient samples, ZNF132 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF132 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
